

The Effect of Replacing Sitting With Standing on Cardiovascular Risk Factors: A Systematic Review and Meta-analysis

Farzane Saeidifard, MD; Jose R. Medina-Inojosa, MD, MSc; Marta Supervia, MD, MSc; Thomas P. Olson, PhD; Virend K. Somers, MD, PhD; Larry J. Prokop, MLS; Gorazd B. Stokin, MD, PhD; and Francisco Lopez-Jimenez, MD, MSc

Abstract

Objective: To investigate the effect of replacing sitting with standing on cardiovascular risk factors tested in clinical trials.

Methods: We searched databases from inception up to August 28, 2019, for studies examining the effect of replacing sitting with standing on fasting blood glucose, fasting insulin, and lipid levels; blood pressure; body fat mass; weight; and waist circumference in healthy adults. Differences in mean \pm SD values were used for pooling the data and calculating the mean differences and CIs.

Results: The search found 3507 abstracts. Nine clinical trials (8 randomized and 1 nonrandomized) with 877 (64.4% [n=565] women) participants met all inclusion criteria. The mean \pm SD age was 45.34 \pm 5.41 years; mean follow-up was 3.81 months, and mean difference in standing time between the intervention and control groups was 1.33 hours per day. The follow-up fasting blood glucose and body fat mass values were slightly but significantly lower than baseline records in the intervention groups compared with control groups (-2.53; 95% Cl, -4.27 to -0.79 mg/dL; and -0.75; 95% Cl, -0.91 to -0.59 kg). The analysis for fasting insulin levels, lipid levels, blood pressure, weight, and waist circumference revealed no significant differences.

Conclusion: Replacing sitting with standing can result in very small but statistically significant decreases in fasting blood glucose levels and body fat mass with no significant effect on lipid levels, blood pressure, weight, and waist circumference. Replacing sitting with standing can be used as an adjunctive intervention to decrease the burden of cardiovascular risk factors but cannot be used as an alternative to physical activity to decrease sedentary time.

© 2020 THE AUTHORS. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) = Mayo Clin Proc Inn Qual Out 2020;4(6):611-626

ardiovascular disease (CVD), especially ischemic heart disease, is the leading cause of death worldwide.¹ The number of deaths from CVD has increased globally from 5.74 to 8.14 million from 1990 to 2013, while the number of crude deaths has decreased from 9.266 per 1000 to 7.556 per 1000 during the same period.² Major modifiable risk factors for CVD explain most CVD events and several factors coexist because they share similar causes, namely sedentary lifestyle and poor diet. The CVD risk factors representing the spectrum of cardiometabolic dysregulation include elevated blood glucose levels; insulin resistance; abnormal lipid levels; increased waist circumference (WC), waist to hip ratio, and body fat mass (BFM); and high blood pressure.^{3,4} Accordingly, attenuating these risk factors through lifestyle changes such as increasing physical activity and decreasing sedentary time⁵ could play a major role in reducing the burden of CVD.

Sedentary behavior, defined as time spent with a low rate of energy expenditure (≤ 1.5 metabolic equivalent tasks)^{6,7} during waking hours and commonly represented by sitting time, is associated with CVD and with CVD



From the Division of Preventive Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.S., J.R.M.-I., M.S., T.P.O., V.K.S., F.L.-J.); Department of Medicine, Northwell Health, The Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, New York, NY (F.S.); Gregorio Marañón

Affiliations continued at the end of this article.




FIGURE 1. Preferred Reporting Items for Systematic Reviews and Metaanalyses flow diagram details the literature search and number of included and excluded studies with reasons for exclusion in each stage.

risk factors, including obesity, diabetes, hypertension, and hyperlipidemia.⁸⁻¹² In modern society, adults are highly sedentary, while they might be physically active by the definition of having 150 or more minutes of moderate to vigorous physical activity per week. It is shown that the average monitored sitting time is about 7.7 hours per day in the United States (equal to 54.9% of waking hours)¹³ and selfreported sitting time is 5.15 hours per day in European countries.¹⁴

In recent years, more studies have been focusing on testing the effect of replacing sedentary time with different kinds of activities as an intervention to improve CVD risk factors and mortality.¹⁵ Observational data have consistently demonstrated that shorter sedentary time, or sitting time, is associated with healthier measures of WC, body mass index (BMI), triglyceride (TG) levels, and 2-hour plasma glucose levels.¹⁶⁻¹⁸ It also has been shown that replacing sitting with other activities including walking has a significant association with reduced CVD mortality.¹⁵ However, the overwhelming evidence supporting the hypothesis that avoiding sedentary time improves CVD risk factors is observational in nature and therefore more prone to bias because people who avoid sedentary behavior tend to be more physically active and healthier.¹⁹⁻²¹

Nevertheless, in recent years there has been increased emphasis on standing to reduce sedentary time, under the assumption that nonsitting activities with minimal additional caloric expenditure, such as just standing, would be beneficial.²² Although replacing sitting with standing may help prevent weight gain,²² the effect of standing vs sitting to control CVD risk factors is controversial.²³⁻²⁸

Therefore, we aimed to systematically review and first, demonstrate how much evidence has been produced to examine the actual effect of using widely growing standing desks on health, and second, quantitatively synthesize the effect of replacing sitting time with standing on sedentary lifestyle—related CVD risk factors in adults as tested in randomized and nonrandomized controlled trials.

METHODS

This systematic review and meta-analysis was designed according to the *Cochrane Handbook of Systematic Reviews* and is approved by Mayo Clinic Institutional Review Board. The study is being reported based on the 2015 Preferred Reporting Items for Systematic Reviews and Meta-analysis statement.²⁹

Studies were eligible if they met all of the following criteria. (1) Design: published and unpublished experiments with a parallel randomized or nonrandomized comparison group or crossover clinical trials. (2) Participants: nonpregnant and nonlactating healthy adults. (3) Intervention: replacing sitting time with standing for at least 30 minutes per day. (4) Comparison: sitting without any significant break including standing or walking. (5) Outcome: changes in CVD risk factors, including obesity measures (weight, WC, waist to hip ratio, and BFM), cardiometabolic biomarkers (fasting blood glucose (FBG), fasting insulin (FI), and lipids), and systemic blood pressure. (6) Follow-up: a minimum of 5 consecutive days. We had no time or language restriction.

TABLE. Base	eline Characteristic	s of Studies That	Examined the		Sitting Time Wit	h Standing on Different Cardiovascular Risk Factors		
Reference, year	No. of Partici- pants (interven- tion, control)	Participants' Mean Age (y)	Follow-up (mo)	Δ Time of Standing (h/d), intervention — control	Study Design	Setting (PICO)	Study Location	Risk of Bias in Individual Studies
Aadahl et al, ³¹ 2014	81, 68	52	6	0.44	RCT	 Participants: Sedentary adults recruited from the population-based Health 2010 Study who self-reported at least 3.5 h of daily leisure-time sedentary behaviors, had comprehension of Danish language, self-reported maximum 8 h/wk of vigorous physical activity without a handicap or functional limitation Intervention: 4 individual theory-based counseling sessions to encourage for more standing and less sitting Comparison: Participants with usual lifestyle in the control group Outcomes: Sitting time, breaks in sitting time, BMI, weight, waist circumference, body fat, total cholesterol, HDL-C, LDL-C, triglycerides, fasting blood glucose, fasting insulin, fasting HbA_{1c}, HOMA 	Denmark	Low
Alkhajah et al, ³² 2012	18, 13	36.2	3	3.54	RCT	 Participants: Office workers who used a nonadjustable work surface and desktop computer Intervention: Installation of commercially available sit—stand workstation Comparisone: Participants doing usual day-to-day activities Outcomes: Changes in sitting and standing time, fasting total cholesterol, HDL-C, triglycerides, fasting glucose 	Australia	Unclear
Butler et al ³³ 2018	21, 21	22.7	0.7	0.71	CRCT	Participants: Healthy college students Intervention: Installing standing desks Comparisone: Participants who were seated Outcomes: Changes in fasting glucose, fasting triglycerides, HDL-C, blood pressure (systolic and diastolic)		
Danquah et al, ³⁴ 2016	173, 144	45.5	3	0.716	RCT	 Participants: Practitioners and health workers in municipalities and private workplaces Intervention: Appointment of local ambassadors, management support, environmental changes, a lecture, a workshop to encourage for more standing and less sitting Comparison: Participants in control group who did not receive the interventions Outcomes: Changes in waist circumference and body fat percentage 	Denmark and Greenland	Low
							Continue	ed on next page

613

Reference, year	No. of Partici- pants (interven- tion, control)	Participants' Mean Age (y)	Follow-up (mo)	Δ Time of Standing (h/d), intervention — control	Study Design	Setting (PICO)	Study Location	Risk of Bias in Individual Studies
Graves et al. ²⁶ 2015	23, 21	38.6	2	1.21	RCT	 Participants: Asymptomatic full-time office workers Intervention: Installing sit-stand workstation on participants' workplace desk for 8 wk Comparison: Participants in control group who did not receive interventions Outcomes: Sitting, standing, and walking time; vascular outcomes including endothelial dysfunction, carotid artery intima media thickness, systolic and diastolic blood pressure; fasting blood glucose, total cholesterol, triglycerides, musculoskeletal discomfort/pain, anthropometric, sociodemographic, work-related and office environment characteristics, acceptability and feasibility of using sit-stand workstation 	England	Unclear
Healy et al, ³⁵ 2013	18, 18	43.2	I	2.13	NRCT	 Participants: Sample of community-dwelling Australian adults Interventions: 45-min researcher-led consultation, holding workshops, installing dual display sit-stand workstations, 30-min face-to-face consultation with each intervention participant, followed by 3 telephone calls (1/wk) Comparison: Participants in control group who were advised to maintain usual work practices Outcomes: Changes in sitting, standing, and moving time; weight, waist circumference, hip circumference, fat-free mass, fat mass, total cholesterol, triglycerides, HDL-C, LDL-C, fasting glucose, fasting insulin, systolic and diastolic blood pressure 	Australia	Unclear
Healy et al, ³⁶ 2017	136, 95	45.6	12	0.6	RCT	 Participants: Staff of a large single public service organization Intervention: Senior management support, recruitment of team champion, emails from team champion promoting the intervention messages, installing sit-stand workstations, health coaching, goal setting and tracking Comparison: Participants in control group who were advised to maintain usual work practices Outcomes: Cardiometabolic risk score, changes in weight, fat mass, waist circumference, HDL-C, LDL-C, triglycerides, fasting blood glucose, fasting insulin, HOMA, systolic and diastolic blood pressure 	Australia	Low

TABLE. Co	ntinued							
Reference, year	No. of Partici- pants (interven- tion, control)	Participants' Mean Age (y)	Follow-up (mo)	∆ Time of Standing (h/d), intervention – control	Study Design	Setting (PICO)	Study Location	Risk of Bias in Individual Studies
MacEwen et al, ³⁷ 2017	15, 10	45.48	3	1.31	RCT	 Participants: Overweight/obese sedentary office workers, mean BMI of 35.8 kg/m² Intervention: Installing height-adjustable desks Comparison: Participants in seated work posture Outcomes: Changes in weight, BMI, waist circumference, body fat mass, systolic and diastolic blood pressure, total cholesterol, triglycerides, HDL-C, LDL-C, fasting blood glucose, HbA_{1c}, Vo_{2max}, aortic augmentation index, subendocardial variablity, behavioral outcomes 		
Thorp et al, ²⁴ 2014	23, 23	48.2	0.17	3.91	Crossover RCT	 Participants: Overweight/obese sedentary office workers, 17 men and 6 women, BMI= 29.6 kg/m² Intervention: Installing electric height-adjustable workstation Comparison: Participants in seated work posture Outcomes: Changes in weight, waist circumference, fasting glucose, fasting insulin, fasting triglycerides 	Australia	Low

STANDING AND CARDIOVASCULAR RISK FACTORS

BMI = body mass index; CRCT = controlled randomized clinical trial; HbA_{1c}, glycated hemoglobin; HDL-C = high-density lipoprotein cholesterol; HOMA = homeostatic model assessment; LDL-C = low-density lipoprotein cholesterol; NRCT = nonrandomized clinical trial; PICO = participants, intervention, comparison, outcomes; RCT = randomized controlled trial; Vo_{2max}, maximum oxygen consumption.

An expert librarian searched different databases, including MEDLINE, EMBASE, Scopus, Turning Research Into Practice Database, Web of Science, Google Scholar, and Cumulative Index of Nursing and Allied Health Literature since inception up to August 28, 2019. The Supplemental Appendix (available online at https://mcpiqojournal.org) shows the search strategy and the terms used for searching MEDLINE.

We searched through the references of the included studies and similar studies for additional reports. Trial registries were other sources of the handsearching for finding gray literature, specifically unpublished studies, as defined by the Cochrane handbook.³⁰ No ongoing trial was found in our search. The authors of included studies were also contacted for any similar published or unpublished studies. Before finalizing the analysis, we updated our search for the studies with publication dates after completion of our original search.

Three independent investigators (F.S., J.R.M.-I., and M.S.) reviewed the titles and abstracts of the studies, which were identified through the original search, in parallel and using an online reference manager software (Covidence). Duplicates were removed by the librarian and also during the screening by the software. Disagreements were resolved using consensus and, if not possible, using arbiappropriate by the senior tration as investigator (F.L.-J.). The investigators then assessed the full text of the included titles and abstracts for eligibility, independently and in parallel, to capture the most relevant studies for data extraction and analysis. The κ statistic was used to examine the agreement between investigators in each stage of the screening.

A database was prepared with all predefined variables to collect and to be used independently and in duplicate by investigators for the data extraction. Two investigators extracted the data of the included studies, and the third investigator evaluated the results to examine and confirm the concordance between the 2 investigators. The extracted data included study characteristics (author, year of publication, design, location of the study, and risk of bias), participant characteristics (including number of participants, age, sex, and health status), intervention characteristics (including time spent standing in a day and follow-up of the participants in different groups), and mean \pm SD of baseline and follow-up of both the intervention and control groups for different cardiometabolic biomarkers and blood pressure. In case additional information was needed, the authors of the study would be contacted by email.

The Cochrane Collaboration's tool was used to assess the risk of bias in individual The investigators independently studies. answered the following questions for each study: Was the allocation sequence adequately generated? Was allocation adequately concealed? Was the knowledge of the allocated interventions adequately prevented during the study? Were incomplete outcome data adequately addressed? Are reports of the study free of suggestion of selective outcome reporting? Was the study apparently free of other problems that could put it at a risk of bias? The reviewers would answer "yes" to the questions if they found evidence of controlling that bias in the study, the answer "no" meant the study could not control the bias, and "unclear" was used when the reviewers were not able to draw a conclusion regarding the presence or absence of that bias in the study. The number of yes, no, and unclear responses resulted in the overall risk of bias in each study. The studies were also assessed for risk of bias in outcome measurement and analysis.

We calculated the difference in mean \pm SD of the baseline and follow-up for both the intervention and control groups in each study and for each risk factor. RevMan, version 5.3, Cochrane Collaboration tool, was used to pool the data across individual studies using a random-effect inverse variance model. The result of the meta-analysis for each risk factor was reported in mean difference and 95% CI. To analyze between-study heterogeneity we used different forest plots and calculated the I^2 statistic. The forest plots were inspected visually and I^2 values greater than 75% were classified as considerable heterogeneity. In case considerable heterogeneity was discovered between studies, we would use subgroup analysis and sensitivity analysis, if possible, to explain the source of the heterogeneity. Prespecified subgroup analyses were defined based on the duration of standing in the

Torp 2014 -1.98 0.47 23 0.01 0.49 23 17.3% -1.99 [-2.27,-1.71] MacEwen 2017 -3.96 3.96 15 -8.65 1.8 10 13.4% 4.69 [2.40, 6.98] Healy 2017 1.26 19.22 136 7.39 22.13 95 6.3% -6.13 [-11.63, -0.63] Healy 2013 -7.75 6.13 18 -1.8 5.45 18 9.5% -5.95 [-9.74, -2.16] Graves 2015 -12.8 4.32 23 -6.49 3.26 21 13.5% -6.31 [-8.56, -4.06] Butler 2018 -1.6 1.74 21 0.8 1.81 21 16.3% -2.40 [-3.47, -1.33] Adahl 2012 -0.18 2.52 18 4.32 3.42 13 13.6% -4.50 [-6.69, -2.31] Aadahl 2014 -3.6 9.01 81 -3.6 12.6 68 10.0% 0.00 [-3.58, 3.58] Heterogeneity:Tau ² =4.52; Chl ² =59.76, df=7 (P<.00001); l ² =88% 269 100.0% -2.53 [-4.27, -0.79]	Study or subgroup	Interv Mean [mg/dl]	ention SD [mg/dl]	Total	Con Mean [mg/dl]	trol SD [mg/dl]	Total	Weight	Mean difference IV, random, 95% CI [mg/dl]	Mean difference IV, random, 95% CI [mg/dl]
Mackwen 2017 -3.96 3.96 15 -8.65 1.8 10 13.4% 4.69 12.40 6.98 Healy 2017 1.26 19.22 136 7.39 22.13 95 6.3% 6.13 [-11.63, -0.63] Healy 2013 -7.75 6.13 18 -1.8 5.45 18 9.5% -5.95 [-9.74, -2.16] Graves 2015 -12.8 4.32 23 -6.49 3.26 21 13.5% -6.31 [-8.56, -4.06] Butler 2018 -1.6 1.74 21 0.8 1.81 21 16.3% -2.40 [-3.47, -1.33] Alkhajah 2012 -0.18 2.52 18 4.32 3.42 13 13.6% -4.50 [-6.69, -2.31] Aadahl 2014 -3.6 9.01 81 -3.6 12.6 68 10.0% 0.00 [-3.58, 3.58] Heterogeneity:Tau ² =4.52; Chl ² =59.76, df=7 (P<.00001); l ² =88% 269 100.0% -2.53 [-4.27, -0.79] •	, , ,	-	÷		- 0 -	- 0 -		5		
Heavy 2013 −7.75 6.13 18 −1.8 5.45 18 9.5% −5.95 [−9.74, −2.16] Graves 2015 −12.8 4.32 23 −6.49 3.26 21 13.5% −6.31 [−8.56, −4.06] Butler 2018 −1.6 1.74 21 0.8 1.81 21 16.3% −2.40 [−3.47, −1.33] Alkhajah 2012 −0.18 2.52 18 4.32 3.42 13 13.6% −4.50 [−6.69, −2.31] Aadahl 2014 −3.6 9.01 81 −3.6 12.6 68 0.0% 0.00 [−3.58, 3.58] Total (95% CI) 335 269 100.0% −2.53 [−4.27, −0.79] ◆ Heterogeneity:Tau ² =4.52; Chi ² =59.76, df=7 (P<.00001); l ² =88% 58% −2.53 [−4.27, −0.79] ◆	MacEwen 2017								L . J	
Graves 2015 -12.8 4.32 23 -6.49 3.26 21 13.5% -6.31 [-8.56, -4.06] Butler 2018 -1.6 1.74 21 0.8 1.81 21 16.3% -2.40 [-3.47, -1.33] Alkhajah 2012 -0.18 2.52 18 4.32 3.42 13 13.6% -4.50 [-6.69, -2.31] Aadahl 2014 -3.6 9.01 81 -3.6 12.6 68 10.0% 0.00 [-3.58, 3.58] Total (95% CI) 335 269 100.0% -2.53 [-4.27, -0.79] - Heterogeneity: Tau ² =4.52; Chi ² =59.76, df=7 (P<00001); l ² =88% - - - - -	Healy 2017	1.26	19.22	136	7.39	22.13	95	6.3%	-6.13 [-11.63, -0.63]	
Butter 2018 -1.6 1.74 21 0.8 1.81 21 16.3% -2.40 [-3.47, -1.3] Alkhajah 2012 -0.18 2.52 18 4.32 3.42 13 13.6% -4.50 [-6.69, -2.31] Aadahl 2014 -3.6 9.01 81 -3.6 12.6 68 10.0% 0.00 [-3.58, 3.58] Total (95% Cl) 335 269 100.0% -2.53 [-4.27, -0.79]	Healy 2013	-7.75	6.13	18	-1.8	5.45	18	9.5%	-5.95 [-9.74, -2.16]	_
Alkhajah 2012 -0.18 2.52 18 4.32 3.42 13 13.6% -4.50 [-6.69, -2.31] Aadahl 2014 -3.6 9.01 81 -3.6 12.6 68 10.0% 0.00 [-3.58, 3.58] Total (95% Cl) 335 269 100.0% -2.53 [-4.27, -0.79] Heterogeneity: Tau ² =4.52; Chi ² =59.76, df=7 (P<00001); l ² =88%	Graves 2015	-12.8	4.32	23	-6.49	3.26	21	13.5%	-6.31 [-8.56, -4.06]	
Aadahl 2014 -3.6 9.01 81 -3.6 12.6 68 10.0% 0.00 [-3.58, 3.58] Total (95% Cl) 335 269 100.0% -2.53 [-4.27, -0.79] Heterogeneity: Tau ² =4.52; Chi ² =59.76, df=7 (P<.00001); l ² =88%	Butler 2018	-1.6	1.74	21	0.8	1.81	21	16.3%	-2.40 [-3.47, -1.33]	-
Total (95% Cl) 335 269 100.0% -2.53 [-4.27, -0.79] Heterogeneity: Tau ² =4.52; Chi ² =59.76, df=7 (P<.00001); l ² =88%	Alkhajah 2012	-0.18	2.52	18	4.32	3.42	13	13.6%	-4.50 [-6.69, -2.31]	
Heterogeneity:Tau ² =4.52; Chi ² =59.76, df=7 (P<.00001); l ² =88%	Aadahl 2014	-3.6	9.01	81	-3.6	12.6	68	10.0%	0.00 [-3.58, 3.58]	
	Total (95% CI)			335			269	100.0%	-2.53 [-4.27, -0.79]	•
Test for overall effect: Z=2.85 (P=.004) -20 -10 0 10 2	Heterogeneity:Tau ² =4	4.52; Chi ² =59.76, o	df=7 (P<.0000	I); I ² =88	1%					
	Test for overall effect:	Z=2.85 (P=.004)								-20 -10 0 10 20

FIGURE 2. The overall weighted mean difference and 95% Cl of the effect of replacing sitting with standing on fasting blood glucose level. SI conversion factor: To convert glucose values to mmol/L, multiply by 0.0555.

intervention groups, duration of follow-up of participants, and characteristics of participants, such as sex or age.

RESULTS

The original search by the librarian identified 3507 studies, of which 41 met the primary inclusion criteria for full-text assessment. After reviewing the full text, the reviewers agreed on 9 studies with 877 participants for data extraction and pooled analysis. Figure 1 shows the number of studies excluded at each stage of the screening and details the reasons for excluding these studies. All studies were done after 2012, and most were conducted in Australia. The mean \pm SD age of participants was 45.34 \pm 5.41 years, mean follow-up was 3.81 months, and 64.4% (565 of 877) of the participants were women. The mean

 \pm SD difference in standing time between baseline and follow-up in the intervention group was 1.33 hours per day more than the control group. The Table^{24,26,31-37} shows the characteristics of studies included in the systematic review and meta-analysis.

Five of 9 studies had a low risk of bias and 4 had an intermediate risk of bias. The outcome-level risk of bias assessment within individual studies revealed that obesity measures and cardiometabolic biomarkers in all studies were made by staff blinded to group allocation, and in 4 studies, the measurement of blood pressure was blinded to group allocation. None of the studies reported incomplete data. The overall outcome-level risk of bias across the studies was low.

Figures 2-14 are forest plots that detail the differences between baseline and follow-up for

Study or subgroup	Interv Mean [pmol/L]		Total	Con Mean [pmol/L]	trol SD [pmol/L]	Total	Weight	Mean difference IV, random, 95% CI [pmol/L]	Mean difference IV, random, 95% CI [pmol/L]
Aadahl 2014	-6.2	6.	81	-0.4	17.3	68	22.2%	-5.80 [-11.20, -0.40]	
Healy 2013	6.5	12.01	18	6.2	10.06	18	14.5%	0.30 [-6.94, 7.54]	
Healy 2017	6.47	62.1809	136	11.18	61.7052	95	3.5%	-4.71 [-20.93, 11.51]	
Thorp 2014	0.52	2.4	23	0.49	2.28	23	59.9%	0.03 [-1.32, -1.38]	•
Total (95% CI) Heterogeneity:Tau ² =	3.72; Chi ² =4.52, d	f=3 (P=.21); I ² =	258 34%			204	100.0%	-1.39 [-4.49, 1.72]	•
Test for overall effect	t: Z=0.88 (P=.38)								-20 -10 0 10 20 Favours [standing] Favours [sitting]

FIGURE 3. The weighted mean difference and 95% CI of the effect of replacing sitting with standing on fasting blood glucose levels in different subgroups. SI conversion factor: To convert glucose values to mmol/L, multiply by 0.0555.

Study or subgroup	Interv Mean [mg/dl]	ention SD [mg/dl]	Total	Cor Mean [mg/dl]	trol SD [mg/dl]	Total	Weight	Mean difference IV, random, 95% CI [mg/dl]	Mean difference IV, random, 95% CI [mg/dl]
1.2.1 Time of standir	ng ≥2 h								
Thorp 2014	-1.98	0.47	23	-1.8	0.49	23	15.9%	-0.18 [-0.46, 0.10]	+
Healy 2013	-7.75	6.13	18	-1.8	5.45	18	10.3%	-5.95 [-9.74, -2.16]	
Alkhajah 2012	-0.18	2.52	18	4.32	3.42	13	13.5%	-4.50 [-6.69, -2.31]	
Subtotal (95% CI)			59			54	39.8%	-3.26 [-7.12, 0.60]	•
Heterogeneity:Tau ² =	10.17; Chi ² =23.32	, df=2 (P<.000	01); I ² =9	91%					
Test for overall effect	Z=1.65 (P=.10)								
1.2.2 Time of standir	ng <2 h								
MacEwen 2017	-3.96	3.96	15	-8.65	18	10	13.3%	4.69 [2.40, 6.98]	
Healy 2017	1.26	19.22	136	7.39	22.13	95	7.4%	-6.13 [-11.63, -0.63]	
Graves 2015	-I 2.8	4.32	23	-6.49	3.26	21	13.4%	-6.31 [-8.56, -4.06]	
Butler 2018	-1.6	1.74	21	0.8	1.81	21	15.3%	-2.40 [-3.47, -1.33]	-
Aadahl 2014	-3.6	9.01	81	-3.6	12.6	68	10.7%	0.00 [-3.58, 3.58]	_ _
Subtotal (95% CI)			276			215	60.2%	-1.84 [-5.62, 1.93]	-
Heterogeneity:Tau ² =	l 6.08; Chi ² =50.66	, df=4 (P<.000	01); I ² =9	92%					
Test for overall effect	:Z=0.96 (P=.34)								
Total (95% CI)			335			269	100.0%	-2.30 [-4.35, -0.25]	•
Heterogeneity: Tau ² =		df=7 (P<.0000	l); l ² =92	2%					
Test for overall effect			2						-20 -10 0 10 20
Test for subgroup diff	ferences: Chi ² =0.2	6, df=1 (P=.61)), I ² =0%						Favours [standing] Favours [sitting]

FIGURE 4. The overall weighted mean difference and 95% CI of the effect of replacing sitting with standing on fasting blood insulin level.

both intervention and control groups followed by the mean difference (intervention – control) and 95% CI of each risk factor in each study. The risk factors include FBG, FI, TG, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), weight, WC, BFM, systolic blood pressure, and diastolic blood pressure. Standing decreased FBG and BFM values in the intervention groups compared with the control groups (-2.53; 95% CI, -4.27to -0.79 mg/dL [to convert to mmol/L, multiply by 0.0555]; and -0.75, 95% CI, -0.91 to -0.59 kg, respectively). Measurements of other risk factors did not change significantly (Figures 2-14).




FIGURE 5. The weighted mean difference and 95% CI of the effect of replacing sitting with standing on triglyceride levels in different subgroups. SI conversion factor: To convert triglyceride values to mmol/L, multiply by 0.0113.

Study or subgroup	Interve Mean [mg/dl]	entional SD [mg/dl]	Total	Con Mean [mg/dl]		Total	Weight	Mean difference IV, random, 95% CI [mg/dl]	Mean difference IV, random, 95% CI [mg/dl]
Aadahl 2014	-4.68	12.61	81	-1.44	11.89	68	20.0%	-3.24 [-7.18, 0.70]	
Alkhajah 2012	5.22	5.95	18	0.72	4.86	13	20.1%	4.50 [0.69, 8.31]	_
Graves 2015	-11.9	5.4	23	-2.88	4.5	21	21.0%	-9.02 [-11.95, -6.09]	
Healy 2013	-0.18	5.58	18	-3.42	4.68	18	20.6%	3.24 [-0.12, 6.60]	
MacEwen 2017	-4.32	5.76	15	-0.36	7.4	10	18.3%	-3.96 [-9.39, 1.47]	
Total (95% CI)			155			130	100.0%	-1.69 [-7.22, 3.83]	-
Heterogeneity:Tau ² = Test for overall effec		, df=4 (P<.000	001); I ² =	=91%					-20 -10 0 10 20
									Favours [standing] Favours [sitting]

FIGURE 6. The overall weighted mean difference and 95% Cl of the effect of replacing sitting with standing on low-density lipoprotein cholesterol level. SI conversion factor: To convert low-density lipoprotein cholesterol values to mmol/L, multiply by 0.0259.

Examination of heterogeneity among studies for different risk factors showed that between-study heterogeneity for FI was not important (I^2 =34%), whereas for systolic blood pressure, WC, LDL-C, and TG values, it was moderate to substantial (I^2 =64%, 58%, 59%, and 71%, respectively) and for FBG, TC, HDL-C, and diastolic blood pressure values was considerable (I^2 =88%, 91%, 84%, and 92%, respectively).

The strength of our recommendations using the Grading of Recommendations, Assessment, Development and Evaluations system was moderate.^{38,39} The risk of bias was low in most studies, mainly in those that were included for FBG and BFM; the results of the studies were direct (low level of indirectness); the results of the studies were consistent because heterogeneity was less than 75% among most studies (low to moderate level of inconsistency); the results were imprecise about nonsignificant outcomes (broad CIs); and finally, the publication bias was low (mainly for FBG and BFM; we used different studies for different outcomes; therefore, having a funnel plot for all included studies was not possible).

DISCUSSION

The present study aimed to investigate the effect of replacing sitting time with standing on CVD risk factors through a systematic review and meta-analysis. The results of the study demonstrated that replacing an average of 1.33 hours of sitting per day with standing for an average of 4 months can modestly decrease FBG and BFM values. There were no significant changes in FI, body weight, WC, blood lipid levels (including TG, TC, HDL-C, and LDL-C), or blood pressure after replacing sitting with standing.




FIGURE 7. The overall weighted mean difference and 95% CI of the effect of replacing sitting with standing on triglyceride level. SI conversion factor: To convert triglyceride values to mmol/L, multiply by 0.0113.

Stuty or subgroup	Inter Mean [mg/dl]	vention SD [mg/dl]	Total	Co Mean [mg/dl]	ntrol SD [mg/dl]	Total	Weight	Mean difference IV, random, 95% CI [mg/dl]	Mean difference IV, random, 95% CI [mg/dl]
Aadahl 2014	-3.78	10.8	81	-1.08	9	68	26.9%	-2.70 [-5.88, 0.48]	
Healy 2013	-0.54	5.4	18	-2.16	3.96	18	27.4%	1.62 [-1.47, 4.71]	
Healy 2017	-1.8	11.67	136	-1.62	14.13	95	25.2%	-0.18 [-3.63, 3.27]	_ _
MacEwen 2017	-3.96	4.86	15	1.08	5.76	10	20.5%	-5.04 [-9.38, -0.70]	
Total (95% CI)			250			191	100.0%	-1.36 [-4.08, 1.37]	•
Heterogeneity:Tau ² =4 Test for overall effect:2		=3 (P=.06); I ² =	=59%					-	-20 -10 0 10 20 Favours [standing] Favours [sitting]

FIGURE 8. The overall weighted mean difference and 95% Cl of the effect of replacing sitting with standing on total cholesterol level. SI conversion factor: To convert total cholesterol values to mmol/L, multiply by 0.0259.

Body Fat Mass

Our results showed a small but significant effect of replacing sitting with standing on BFM. It has been shown that increasing daily energy expenditure, even with substituting sitting with slow-pace walking, which is not classified as an exercise, has a promising effect on body composition, in particular, body fat content.^{40,41} We have recently demonstrated that standing expends significantly more energy (0.15 kcal/min) than sitting and standing for 6 hours per day for a year could have a significant effect on energy expenditure,² emphasizing that standing can theoretically decrease BFM over time. The relatively short mean duration of standing and the lowintensity nature of the intervention could potentially explain the small amount of change in BFM that was observed in this study.

Waist Circumference

The nonsignificant results for WC (P=0.64) and weight (P=0.21) could be explained by reviewing the limitations in methods and instruments of the original studies and the importance of the variables. Weight is an inaccurate measure for evaluating body composition at the individual level.42,43 Additionally, manual measurement of WC is prone to numerous errors and has shown significant inter- and intraobserver variability, limiting the ability to detect small differences in WC over time.44,45 This can explain the significant reduction in WC that was observed in the study by Aadahl et al,³¹ which contrasted with the other studies that did not report significant changes in WC. It is also possible that small changes in the amount of visceral fat may not be reflected in changes in WC. Despite these differences, there is also the possibility that standing vs sitting may not lead to significant weight loss or improvements in the distribution of fat, particularly with modest durations of standing or because of substitution of fat with muscle. In contrast, observational studies have shown a significant reduction in weight and BMI in people who use sit-stand desks in comparison to the people who work seated.^{46,47}

Fasting Blood Glucose

A modest effect on FBG level was observed when replacing sitting with standing. Muscle has a significant role in the regulation of blood glucose. Muscle contraction increases the number of glucose receptors and glucose uptake.48 Standing involves more muscles than sitting,49 and this can be a physiologic explanation of our results. However, considering the small difference in the number and intensity of muscle contractions between sitting and standing, the difference in glucose uptake between these 2 postures is expected to be small. Overall, the result of this study suggests some benefits for the prevention of diabetes and at least theoretically for the management of patients with diabetes.

Our study also showed no effect of standing on blood lipid level, similar to what prior studies have shown on the effect of replacing sitting with either aerobic exercise or lightintensity activities on blood lipid levels.^{9,50,51}

Blood Pressure

The present study did not show a significant change in blood pressure after replacing sitting

Church an automation		vention	Takal		ontrol	Tatal	Wainh4	Mean difference	Mean difference
itudy or subgroup	Mean [mg/dl]	SD [mg/dl]	Iotal	Mean [mg/dl]	SD [mg/al]	Iotal	weight	IV, random, 95% CI [mg/dl]	IV, random, 95% CI [mg/dl]
.5.1 Time of standing	l ≥2 h								
Alkhajah 2012	-0.18	5.4	18	-0.36	2.34	13	13.2%	0.18 [-2.62, 2.98]	
Healy 2013	3.06	5.76	18	0	9.2	18	6.9%	3.06 [-1.95, 8.07]	+
Thorp 2014	0.24	0.047	23	0.22	0.047	23	22.8%	0.02 [-0.01, 0.05]	•
Subtotal (95% CI)			59			54	42.8%	0.02 [-0.01, 0.05]	
Heterogeneity: Tau ² =0.0 Test for overall effect: Z		=2 (P=.49); I ² =	=0%						
1.5.2 Time of standing	ı<2 h								
Aadahl 2014	-1.08	7.21	81	-0.36	10.8	68	12.4%	-0.72 [-3.73, 2.29]	
Butler 2018	-11	8.19	21	0.6	9.12	21	6.4%	-11.60 [-16.84, -6.36]	
Graves 2015	-0.72	3.78	23	0.72	3.78	21	15.6%	-1.44 [-3.68, 0.80]	
Healy 2017	-0.36	9.55	136	0.18	9.72	95	14.3%	-0.54 [-3.07, 1.99]	
MacEwen 2017	1.26	5.58	15	0	5.72	10	8.4%	1.26 [-3.03, 5.55]	
Subtotal (95% CI)	1120	2.00	276	0		215	57.2%	-2.10 [-5.01, 0.82]	
Heterogeneity: Tau ² =7.9 Test for overall effect: 2		f=4 (P=.002);	l ² =76%	6					
Total (95% CI)			335			269	100.0%	-0.79 [-2.36, 0.78]	•
Test for overall effect: Z	Z=0.99 (P=.32)	()							– 20 –10 0 10 20 Favours (standing) Favours (sitting)
Test for overall effect: Z Test for subgroup differ	z=0.99 (P=.32) rences: Chi ² =2.03 Inter	, df=1 (P=.15), I ² =50	.6% Cc	ontrol	Tatal	W-:	Mean difference	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: Z Test for subgroup differ Study or subgroup	Z=0.99 (P=.32) rences: Chi ² =2.03 Inter Mean [mg/dl]	, df=1 (P=.15), I ² =50	.6%		Total	Weight	Mean difference IV, random, 95% CI [mg/dl]	Favours [standing] Favours [sitting]
Test for overall effect: Z Test for subgroup differ Study or subgroup 1.5.3 Time of follow-u	Z=0.99 (P=.32) rences: Chi ² =2.03 Inter Mean [mg/dl] p ≥3 months	, df=1 (P=.15 vention SD [mg/dl]), I ² =50 Total	.6% Cc Mean [mg/dl]	SD [mg/dl]		-	IV, random, 95% CI [mg/dl]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: Z Test for subgroup differ Study or subgroup 1.5.3 Time of follow-u Aadahl 2014	z=0.99 (P=.32) rences: Chi ² =2.03 Inter Mean [mg/dl] p ≥3 months -1.08	vention SD [mg/dl]), I ² =50 Total 81	.6% Cc Mean [mg/dl] –0.36	SD [mg/dl]	68	12.4%	IV. random. 95% Cl [mg/dl]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: Z Test for subgroup differ Study or subgroup 1.5.3 Time of follow-u Aadahl 2014 Alkhajah 2012	z=0.99 (P=.32) rences: Chi ² =2.03 Mean [mg/dl] p ≥3 months -1.08 -0.18	vention SD [mg/dl] 7.21 5.4), I ² =50 Total 81 18	.6% Cc Mean [mg/dl] -0.36 -0.36	SD [mg/dl] 10.8 2.34	68 3	12.4%	IV. random, 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: Z Test for subgroup differ Study or subgroup 1.5.3 Time of follow-u Aadahl 2014 Alkhajah 2012 Healy 2017	Z=0.99 (P=.32) rences: Chi ² =2.03 Mean [mg/dl] p ≥3 months -1.08 -0.18 -0.36	vention SD [mg/dl] 7.21 5.4 9.55), I ² =50 Total 81 18 136	.6% Mean [mg/dl] -0.36 -0.36 0.18	SD [mg/dl] 10.8 2.34 9.72	68 13 95	2.4% 3.2% 4.3%	IV, random, 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98] -0.54 [-3.07, 1.99]	Favours [standing] Favours [sitting] Mean difference
Heterogeneity: Tau ² =2.1 Test for overall effect: Z Test for subgroup differ Study or subgroup 1.5.3 Time of follow-u Aadahl 2014 Alkhajah 2012 Healy 2017 MacEwen 2017 Subtral (95% C)	z=0.99 (P=.32) rences: Chi ² =2.03 Mean [mg/dl] p ≥3 months -1.08 -0.18	vention SD [mg/dl] 7.21 5.4), I ² =50 Total 81 18 136 15	.6% Cc Mean [mg/dl] -0.36 -0.36	SD [mg/dl] 10.8 2.34	68 13 95 10	2.4% 3.2% 4.3% 8.4%	IV. random. 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98] -0.54 [-3.07, 1.99] 1.26 [-3.03, 5.55]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: 2 Test for subgroup differ Study or subgroup 1.5.3 Time of follow-up Aadahl 2014 Alkhajah 2012 Healy 2017 Subtotal (95% CI) Heterogeneity: Tau ² =0.0	Z=0.99 (P=.32) rences: Chi ² =2.03 Mean [mg/dl] p ≥3 months -0.18 -0.36 1.26 00; Chi ² =0.70, df ²	vention SD [mg/dl] 7.21 5.4 9.55 5.58), I ² =50 Total 81 18 136 15 250	.6% Mean [mg/dl] -0.36 -0.36 0.18	SD [mg/dl] 10.8 2.34 9.72	68 13 95	2.4% 3.2% 4.3%	IV, random, 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98] -0.54 [-3.07, 1.99]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: 2 Test for subgroup differ Study or subgroup 1.5.3 Time of follow-up Aadahl 2014 Alkhajah 2012 Healy 2017 MacEwen 2017 Subtotal (95% CI) Heterogeneity: Tau ² =00 Test for overall effect: 2	Z=0.99 (P=.32) rences: Chi ² =2.03 Mean [mg/dl] p ≥3 months -1.08 -0.18 -0.36 1.26 00; Chi ² =0.70, dfr Z=0.21 (P=.83)	vention SD [mg/dl] 7.21 5.4 9.55 5.58), I ² =50 Total 81 18 136 15 250	.6% Mean [mg/dl] -0.36 -0.36 0.18	SD [mg/dl] 10.8 2.34 9.72	68 13 95 10	2.4% 3.2% 4.3% 8.4%	IV. random. 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98] -0.54 [-3.07, 1.99] 1.26 [-3.03, 5.55]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: 2 Test for subgroup differ Study or subgroup 1.5.3 Time of follow-up Aadahl 2014 Alkhajah 2012 Healy 2017 MacEven 2017 Subtotal (95% CI) Heterogeneity: Tau ² =0.0 Test for overall effect: 2 1.5.4 Time of follow-up	Z=0.99 (P=.32) rences: Chi ² =2.03 Mean [mg/dl] p ≥3 months -1.08 -0.18 -0.36 1.26 00; Chi ² =0.70, dfr Z=0.21 (P=.83)	vention SD [mg/dl] 7.21 5.4 9.55 5.58), I ² =50 Total 81 18 136 15 250	.6% Mean [mg/dl] -0.36 -0.36 0.18	SD [mg/dl] 10.8 2.34 9.72	68 13 95 10	2.4% 3.2% 4.3% 8.4%	IV. random. 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98] -0.54 [-3.07, 1.99] 1.26 [-3.03, 5.55]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: 2 Test for subgroup differ Study or subgroup 1.5.3 Time of follow-up Aadahl 2014 Alkhajah 2012 Healy 2017 MacEwen 2017 Subtotal (95% CI) Heterogeneity: Tau ² =0.0 Test for overall effect: 2 1.5.4 Time of follow-up butler 2018	Z=0.99 (P=.32) rences: Chi ² =2.03 Mean [mg/dt] p ≥3 months -0.18 -0.36 1.26 00; Chi ² =0.70, df: Z=0.21 (P=.83) p <3 months	(P=.15 vention SD [mg/dl] 7.21 5.4 9.55 5.58 =3 (P=.87); 1 ² =), I ² =50 Total 81 18 136 15 250 =0%	.6% Mean [mg/dl] -0.36 0.18 0	SD [mg/dl] 10.8 2.34 9.72 5.22	68 13 95 10 186	12.4% 13.2% 14.3% 8.4% 48.4%	IV. random. 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98] -0.54 [-3.07, 1.99] 1.26 [-3.03, 5.55] -0.16 [-1.66, 1.33]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: 2 Test for subgroup differ Study or subgroup 1.5.3 Time of follow-up Aadahl 2014 Alkhajah 2012 Healy 2017 Subtotal (95% CI) Heterogeneity: Tau ² =0.1 Test for overall effect: 2 1.5.4 Time of follow-up butter 2018 Graves 2015	Z=0.99 (P=.32) rences: Chi ² =2.03 Mean [mg/dl] p ≥3 months -0.18 -0.36 1.26 00; Chi ² =0.70, df Z=0.21 (P=.83) p <3 months -11	(P=.15 vention SD [mg/dl] 7.21 5.4 9.55 5.58 =3 (P=.87); 1 ² = 8.19), I ² =50 Total 81 18 136 15 250 =0% 21	.6% Mean [mg/dl] -0.36 -0.36 0.18 0 0.6	SD [mg/dl] 10.8 2.34 9.72 5.22 9.12	68 13 95 10 186 21	12.4% 13.2% 14.3% 8.4% 48.4% 6.4%	IV, random, 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98] -0.54 [-3.07, 1.99] 1.26 [-3.03, 5.55] -0.16 [-1.66, 1.33]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: Z Test for subgroup differ Study or subgroup 1.5.3 Time of follow-up Aadahl 2014 Alkhajh 2012 Healy 2017 Subtotal (95% Cl) Heterogeneity: Tau ² =0.0 Test for overall effect: Z 1.5.4 Time of follow-up Jutter 2018 Graves 2015 Healy 2013	Z=0.99 (P=.32) rences: Chi ² =2.03 Inter Mean [mg/dl] p ≥3 months -0.18 -0.36 1.26 00; Chi ² =0.70, df Z=0.21 (P=.83) p <3 months -11 -0.72	(P=.15 vention SD [mg/dl] 7.21 5.4 9.55 5.58 =3 (P=.87); 1 ² = 8.19 3.78), I ² =50 Total 81 18 136 15 250 =0% 21 23	.6% Mean [mg/dl] -0.36 -0.36 0.18 0 0.6 0.72	SD [mg/dl] 10.8 2.34 9.72 5.22 9.12 3.78	68 13 95 10 186 21 21	12.4% 13.2% 14.3% 8.4% 48.4% 6.4% 15.6%	IV. random. 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98] -0.54 [-3.07, 1.99] 1.26 [-3.03, 5.55] −0.16 [−1.66, 1.33] -11.60 [-16.84, -6.36] -1.44 [-3.68, 0.80]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: 2 Test for subgroup differ Study or subgroup 1.5.3 Time of follow-u Aadahl 2014 Alkhajah 2012 Healy 2017 Subtotal (95% Cl) Heterogeneity: Tau ² =0.0 Test for overall effect: 2 1.5.4 Time of follow-u putler 2018 Graves 2015 Healy 2013 Thorp 2014	Z=0.99 (P=.32) rences: Chi ² =2.03 Inter Mean [mg/dl] p ≥3 months -0.36 1.26 00; Chi ² =0.70, df Z=0.21 (P=.83) p <3 months -11 -0.72 3.06	(, df=1 (P=.15 vention SD [mg/dl] 7.21 5.4 9.55 5.58 =3 (P=.87); I ² = 8.19 3.78 5.76), I ² =50 Total 81 18 136 15 250 =0% 21 23 18	.6% Mean [mg/dl] 0.36 0.36 0.18 0 0.6 0.72 0	SD [mg/dl] 10.8 2.34 9.72 5.22 9.12 3.78 9.2	68 13 95 10 186 21 21 18	12.4% 13.2% 14.3% 8.4% 48.4% 6.4% 15.6% 6.9%	IV. random. 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98] -0.54 [-3.07, 1.99] 1.26 [-3.03, 5.55] -0.16 [-1.66, 1.33] -11.60 [-16.84, -6.36] -1.44 [-3.68, 0.80] 3.06 [-1.95, 8.07]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: Z Test for subgroup differ Study or subgroup 1.5.3 Time of follow-up Aadahl 2014 Healy 2017 MacEwen 2017 Subtotal (95% CI) Heterogeneity: Tau ² =00 Test for overall effect: Z 1.5.4 Time of follow-up butler 2018 Graves 2015 Healy 2013 Thorp 2014 Subtotal (95% CI) Heterogeneity: Tau ² =8. ⁴	Z=0.99 (P=.32) rences: Chi ² =2.03 Mean [mg/dl] p ≥3 months -1.08 -0.18 -0.36 1.26 00; Chi ² =0.70, dfr Z=0.21 (P=.83) p <3 months -11 -0.72 3.06 0.24 92; Chi ² =21.92, d	(, df=1 (P=.15 vention SD [mg/dl] 7.21 5.4 9.55 5.58 =3 (P=.87);1 ² = 8.19 3.78 5.76 0.047), ² =50 Total 81 18 136 15 250 =0% 21 23 18 23 85	.6% Mean [mg/dl] 0.36 0.36 0.18 0 0 0 0 0 0 0 0 0 0 0 0 0	SD [mg/dl] 10.8 2.34 9.72 5.22 9.12 3.78 9.2	68 13 95 10 186 21 21 18 23	12.4% 13.2% 14.3% 8.4% 48.4% 6.4% 15.6% 6.9% 22.8%	IV. random. 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98] -0.54 [-3.07, 1.99] 1.26 [-3.03, 5.55] -0.16 [-1.66, 1.33] -11.60 [-16.84, -6.36] -1.44 [-3.68, 0.80] 3.06 [-1.95, 8.07] 0.02 [-0.01, 0.05]	Favours [standing] Favours [sitting] Mean difference
Test for overall effect: Z Test for subgroup differ Study or subgroup 1.5.3 Time of follow-u Aadahl 2014 Alkhajah 2012 Healy 2017	Z=0.99 (P=.32) rences: Chi ² =2.03 Mean [mg/dl] p ≥3 months -1.08 -0.18 -0.36 1.26 00; Chi ² =0.70, dfr Z=0.21 (P=.83) p <3 months -11 -0.72 3.06 0.24 92; Chi ² =21.92, d	(, df=1 (P=.15 vention SD [mg/dl] 7.21 5.4 9.55 5.58 =3 (P=.87);1 ² = 8.19 3.78 5.76 0.047), ² =50 Total 81 18 136 15 250 =0% 21 23 18 23 85	.6% Mean [mg/dl] 0.36 0.36 0.18 0 0 0 0 0 0 0 0 0 0 0 0 0	SD [mg/dl] 10.8 2.34 9.72 5.22 9.12 3.78 9.2	68 13 95 10 186 21 21 18 23	12.4% 13.2% 14.3% 8.4% 48.4% 6.4% 15.6% 6.9% 22.8%	IV. random. 95% CI [mg/dl] -0.72 [-3.73, 2.29] 0.18 [-2.62, 2.98] -0.54 [-3.07, 1.99] 1.26 [-3.03, 5.55] -0.16 [-1.66, 1.33] -11.60 [-16.84, -6.36] -1.44 [-3.68, 0.80] 3.06 [-1.95, 8.07] 0.02 [-0.01, 0.05]	Favours [standing] Favours [sitting] Mean difference

FIGURE 9. The overall weighted mean difference and 95% CI of the effect of replacing sitting with standing on high-density lipoprotein cholesterol level. SI conversion factor: To convert high-density lipoprotein cholesterol values to mmol/L, multiply by 0.0259.

with standing, unlike observational studies that showed the opposite results for the effect of replacing sitting time with standing in sedentary individuals.⁴⁶ The lack of blood pressure reduction could be because participants of those studies were not hypertensive and changes in blood pressure in normotensive people who are physically active may be minimal or negligible.^{35,36} Furthermore, standard 1-time blood pressure measurements may not be able to detect small changes in blood pressure. The potential benefits of standing to replace sitting may not be limited to short-term modifications in CVD risk factors. Standing as a major component of nonexercise activity thermogenesis can help decrease sedentary time.^{31,45} In addition, the substitution of sitting with standing can increase daily energy expenditure,^{46,47} which can prevent weight gain in the long term. Although considering that this intervention has minimal effect on CVD risk factors, the definition of a nonsitting position while also performing no active

Study or subgroup	Mean [mmhg]	/ention SD [mmhg]	Total		ntrol SD [mmhg]	Total	Weight	Mean difference IV, random, 95% Cl [mmhg]	Mean difference IV, random, 95% CI [mmhg]
Butler 2018	-2.5	3.23	21	0.5	3.47	21	24.7%	-3.00 [-5.03, -0.97]	-
Graves 2015	-2	3.88	23	-0.6	3.29	21	24.1%	-1.40 [-3.52, 0.72]	
Healy 2013	1.9	4.77	18	-1.2	4.44	18	19.1%	3.10 [0.09, 6.11]	- - -
Healy 2017	-1.03	4.2	136	0.22	13.6	95	16.1%	-1.25 [-4.88, 2.38]	
MacEwen 2017	-1	5.3	15	I	4.02	10	16.0%	-2.00 [-5.66, 1.66]	
Total (95% CI)			213			165	100.0%	-1.01 [-3.06, 1.05]	•
Heterogeneity: Tau ² =	3.37; Chi ² =11.06,	df=4 (P=.03);	l ² =64%	5					
Test for overall effect	Z=0.96 (P=.34)								-20 -10 0 10 20
									Favours [standing] Favours [sitting]

FIGURE 10. The overall weighted mean difference and 95% CI of the effect of replacing sitting with standing on systolic blood pressure.

movements should be revised. Also, the effect of replacing sitting with standing on CVD risk factors can be different in samples with different body composition, BMI, baseline level of physical activity, age, or sex.


This is the first systematic review and meta-analysis on the effect on CVD risk factors of replacing sitting time with standing as an exclusive intervention. Prior systematic reviews have assessed the effects of a range of activities from standing to moderate to vigorous physical activities on CVD risk factors.

In a systematic review by Batacan et al,⁵² the effects of light-intensity activities were shown to have a trivial effect on CVD risk factors in healthy individuals, consistent with our findings. As discussed, that systematic review did not separate different kinds of light-intensity activities from each other to assess for any differential effects on CVD risk factors. Another systematic review and meta-

analysis by Chastin et al⁹ assessed the effect

on CVD risk factors of breaking sitting time with a combination of activities with different intensities. They conducted a meta-analysis (pooling the data from 2 randomized controlled trials) focused on the effect of different kinds of activities on blood glucose levels and showed that breaking sitting time with standing does not have an effect on lowering blood glucose levels. However, our present study reports the results of a metaanalysis of several CVD risk factors, including blood glucose, blood lipid, and blood pressure values, using 8 randomized controlled trials. Our findings provide objective evidence of the effect of using standing as an intervention for a sedentary lifestyle on CVD risk factors.

Our study has several limitations. The number of studies that met inclusion criteria was small; however, all were clinical trials and most studies had a low risk of bias, thus increasing the quality of the meta-analysis. Between-study heterogeneity for more than half




CI 1		erventi			Control		M. 1. I.I.	Std. mean difference	Std. mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, fixed, 95% CI	IV, fixed, 95% Cl
Aadahl 2014	-0.7	7.1	81	0.16	7.9	68	24.3%	-0.11 [-0.44, 0.21]	+
Alkhajah 2012	-0. I	1.53	18	-0.3	1.75	13	5.0%	0.12 [-0.59, 0.83]	
Danquah 2016	-0.2	0.09	173	0. I	0.11	144	24.2%	-3.01 [-3.33, -2.68]	+
Healy 2013	-0.2	4.11	18	-0.9	3.22	18	5.9%	0.19 [-0.47, 0.84]	
Healy 2017	-0.02	3.54	136	0.21	7.17	95	36.8%	-0.04 [-0.31, 0.22]	•
MacEwen 2017	-1.3	3.5	15	-1.6	2.95	10	3.9%	0.09 [-0.71, 0.89]	+
Total (95% CI)			441			348	100.0%	-0.75 [-0.91, -0.59]	*
Heterogeneity: Chi ² =2	247.97, df=	=5 (P<	.00001);	l ² =98%					
Test for overall effect:	Z=9.26 (ł	P<.000	01)						-4 -2 0 2 4
									Favours [standing] Favours [sitting
		- -	aighte	d ma	an d	ifform	nco and	d 95% CL of the a	effect of replacing sitting with

the factors was considerable and subgroup and sensitivity analyses were not possible to be conducted. The results for FBG and BFM were significant but effect sizes were modest. However, the observed effects are not trivial, and standing can be suggested as an adjunct preventive modification for sedentary lifestyles. Our meta-analysis was not significant for several CVD risk factors, which challenges both the effect of replacing sitting with standing on CVD risk and also the definition of sedentary behavior, which is currently "sitting or lying down for a long period." Generalizing the results of the study to people from different cultures and with different extents of dysregulation in CVD risk factors should be done with more caution because all participants of the included studies were healthy and from Denmark and Australia. Because the intensity of the intervention was low, the duration of the intervention and time of follow-up may not have been enough to

make a significant change in risk factors. The average standing time in the intervention group was 1.25 hours per day and the average of follow-up was 4 months, representing a low dose and duration for the intervention under study and limiting the potential effect size, if any. However, the study by Alkhajah et al³² did not show substantial decreases in risk factors, and some measures, such as TG or TC, showed increases in the intervention group.

Regarding the time of follow-up, Healy et al³⁶ with 12 months of follow-up did not report significant changes for almost all factors. A robust randomized ontrolled trial with both longer time of standing and duration of follow-up might be able to resolve some of these questions. Given the modest, negligible, or absent effect of standing vs sitting on CVD risk factors, the assumption that simply replacing sitting with standing time without meaningful differences in physical activity will decrease CVD may be



Study or subgroup	Mean [cm]	vention SD [cm]	Total	Mean [cm]	ntrol SD [cm]	Total	Weight	IV, random, 95% CI [cm]	IV, random, 95% CI [cm]
Aadahl 2014	-1.18	4	81	0.24	2.7	68	24.8%	-1.42 [-2.50, -0.34]	
Alkhajah 2012	1.2	2.6	18	-0.5	2.92	13	13.7%	1.70 [-0.29, 3.69]	
Danquah 2016	-0.7	0.12	173	-0.8	0.125	144	37.4%	0.10 [0.07, 0.13]	<u> </u>
Healy 2013	-0.2	3.95	18	-0.6	4.93	18	8.0%	0.40 [-2.52, 3.32]	
Healy 2017	0.15	8.5	136	1.48	7.7	95	12.8%	-1.33 [-3.44, 0.78]	_
MacEwen 2017	-2	5.4	15	-2	6.4	10	3.4%	0.00 [-4.82, 4.82]	
Total (95% CI)			441			348	100.0%	-0.22 [-1.15, 0.71]	•
Heterogeneity: Tau ² =0.	60; Chi ² =11.87.	df=5 (P=.04	(1): $ ^2 = 58$	%					
Test for overall effect: Z			,,						-4 -2 0 2 4
									Favours [standing] Favours [sitting]

inaccurate. In the meantime, until further prospective and experimental evidence proves beneficial effects of standing vs sitting on measures of cardiometabolic regulation or outcomes, the strategies to decrease sedentary time need to include physical activity.

CONCLUSION

Our study shows that replacing sitting time with standing in healthy adults could decrease FBG and BFM. However, there is no significant change on the remaining cardiovascular risk factors such as lipid, blood pressure, weight, and WC values. This can suggest that replacing sitting with standing can be used as an adjunctive intervention to decrease the burden of cardiovascular risk factors but cannot be used as an alternative to physical activity to decrease sedentary time. Future studies are needed to evaluate both the financial and clinical impact of this intervention on different groups of participants.

SUPPLEMENTAL ONLINE MATERIAL

Supplemental material can be found online at https://mcpiqojournal.org. Supplemental material attached to journal articles has not been edited, and the authors take responsibility for the accuracy of all data.

Abbreviations and Acronyms: BFM = body fat mass; BMI = body mass index; CVD = cardiovascular disease; FBG = fasting blood glucose; FI = fasting insulin; HDL-C = highdensity lipoprotein cholesterol; LDL-C = low-density lipoprotein; TC = total cholesterol; TG = triglycerides; WC = waist circumference

Affiliations (Continued from the first page of this article.): General University Hospital, Gregorio Marañón

Health Research Institute, Madrid, Spain (M.S.); Mayo Clinic Libraries, Mayo Clinic, Rochester, MN (LJ.P.); and International Clinical Research Center (ICRC), St. Anne's University Hospital, Brno, Czech Republic (G.B.S.).

Grant Support: This work was supported by project FNUSA-ICRC (no. CZ.I.05/I.I.00/02.0123), project no. LQ1605 from the National Program of Sustainability II (MEYS CR), and project ICRC-ERA-Human Bridge (no. 316345) and funded by the 7th Framework Program of the European Union, and National Institutes of Health/National Heart, Lung, and Blood Institute grant (no. HL-126638 to TPO).

Potential Competing Interests: The authors declare no competing interests.

Correspondence: Address to Francisco Lopez-Jimenez, MD, MSc, Division of Preventive Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (lopez@mayo.edu; Twitter: @preventingCVD).

ORCID

Farzane Saeidifard: b https://orcid.org/0000-0002-4660-6345; Jose R. Medina-Inojosa: b https://orcid.org/0000-0001-8705-0462; Thomas P. Olson: b https://orcid.org/0000-0002-3446-0414; Francisco Lopez-Jimenez: b https://orcid.org/0000-0001-5788-9734

REFERENCES

- Vishram JKK. Prognostic interactions between cardiovascular risk factors. Dan Med J. 2014;61(7):B4892.
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-171.
- Bundhun PK, Wu ZJ, Chen MH. Impact of modifiable cardiovascular risk factors on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of 100 studies. *Medicine (Baltimore)*. 2015;94(50):e2313.
- Mehta PK, Wei J, Wenger NK. Ischemic heart disease in women: a focus on risk factors. Trends Cardiovasc Med. 2015;25(2):140-151.
- Dempsey PC, Owen N, Biddle SJ, Dunstan DW. Managing sedentary behavior to reduce the risk of diabetes and cardiovascular disease. *Curr Diabetes Rep.* 2014;14(9):522.

- Sedentary Behaviour Research Network. Letter to the editor: standardized use of the terms "sedentary" and "sedentary behaviours". Appl Physiol Nutr Metab. 2012;37:540-542.
- Jette M, Sidney K, Blümchen G. Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity. *Clin Cardiol.* 1990;13(8):555-565.
- Wilmot EG, Edwardson CL, Achana FA, et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. *Diabetologia*. 2012;55(11):2895-2905.
- Chastin SF, Egerton T, Leask C, Stamatakis E. Meta-analysis of the relationship between breaks in sedentary behavior and cardiometabolic health. *Obesity (Silver Spring)*. 2015;23(9):1800-1810.
- Barnes AS. Obesity and sedentary lifestyles: risk for cardiovascular disease in women. Tex Heart Inst J. 2012;39(2):224-227.
- Honda T, Chen S, Kishimoto H, Narazaki K, Kumagai S. Identifying associations between sedentary time and cardiometabolic risk factors in working adults using objective and subjective measures: a cross-sectional analysis. BMC Public Health. 2014;14:1307.
- Henson J, Yates T, Biddle SJ, et al. Associations of objectively measured sedentary behaviour and physical activity with markers of cardiometabolic health. *Diabetologia*. 2013;56(5):1012-1020.
- Matthews CE, Chen KY, Freedson PS, et al. Amount of time spent in sedentary behaviors in the United States, 2003–2004. Am J Epidemiol. 2008;167(7):875-881.
- Bennie JA, Chau JY, van der Ploeg HP, Stamatakis E, Do A, Bauman A. The prevalence and correlates of sitting in European adults-a comparison of 32 Eurobarometer-participating countries. Int J Behav Nutr Phys Act. 2013;10:107.
- Stamatakis E, Gale J, Bauman A, Ekelund U, Hamer M, Ding D. Sitting time, physical activity, and risk of mortality in adults [erratum in: J Am Coll Cardiol. 2019;73(21):2789]. J Am Coll Cardiol. 2019;73(16):2062-2072.
- Peddie MC, Bone JL, Rehrer NJ, Skeaff CM, Gray AR, Peny TL. Breaking prolonged sitting reduces postprandial glycemia in healthy, normal-weight adults: a randomized crossover trial. *Am J Clin Nutr.* 2013;98(2):358-366.
- Healy GN, Dunstan DW, Salmon J, et al. Breaks in sedentary time beneficial associations with metabolic risk. *Diabetes Care*. 2008;31 (4):661-666.
- Dunstan DW, Kingwell BA, Larsen R, et al. Breaking up prolonged sitting reduces postprandial glucose and insulin responses. *Diabetes Care*. 2012;35(5):976-983.
- Hulsegge G, Looman M, Smit HA, Daviglus ML, van der Schouw YT, Verschuren WM. Lifestyle changes in young adulthood and middle age and risk of cardiovascular disease and allcause mortality: the Doetinchem Cohort Study. J Am Heart Assoc. 2016;5(1):e002432.
- Buman MP, Winkler EA, Kurka JM, et al. Reallocating time to sleep, sedentary behaviors, or active behaviors: associations with cardiovascular disease risk biomarkers, NHANES 2005–2006. Am J Epidemiol. 2013;179(3):323-334.
- Chu P, Pandya A, Salomon JA, Goldie SJ, Hunink MG. Comparative effectiveness of personalized lifestyle management strategies for cardiovascular disease risk reduction. J Am Heart Assoc. 2016;5(3):e002737.
- Saeidifard F, Medina-Inojosa JR, Supervia M, et al. Differences of energy expenditure while sitting versus standing: a systematic review and meta-analysis. *Eur J Prev Cardiol.* 2018;25(5):522-538.
- Healy GN, Winkler EA, Owen N, Anuradha S, Dunstan DW. Replacing sitting time with standing or stepping: associations with cardio-metabolic risk biomarkers. *Eur Heart J.* 2015; 36(39):2643-2649.
- Thorp AA, Kingwell BA, Sethi P, Hammond L, Owen N, Dunstan DW. Alternating bouts of sitting and standing attenuate postprandial glucose responses. *Med Sci Sports Exerc.* 2014;46(11):2053-2061.

- Henson J, Davies MJ, Bodicoat DH, et al. Breaking up prolonged sitting with standing or walking attenuates the postprandial metabolic response in postmenopausal women: a randomized acute study. *Diabetes Care*. 2016;39(1):130-138.
- Graves L, Murphy R, Shepherd SO, Cabot J, Hopkins ND. Evaluation of sit-stand workstations in an office setting: a randomised controlled trial. *BMC Public Health*. 2015;15:1145.
- 27. Duvivier BM, Schaper NC, Bremers MA, et al. Minimal intensity physical activity (standing and walking) of longer duration improves insulin action and plasma lipids more than shorter periods of moderate to vigorous exercise (cycling) in sedentary subjects when energy expenditure is comparable. *PloS One*. 2013;8:e55542..
- Bailey DP, Locke CD. Breaking up prolonged sitting with lightintensity walking improves postprandial glycemia, but breaking up sitting with standing does not. J Sci Med Sport. 2015;18(3): 294-298.
- Moher D, Shamseer L, Clarke M, et al; PRISMA-P Group. Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
- Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. In: Higgins JPT, Green S, eds. *Cochrane Book Series*. The Cochrane Collaboration; 2005. ISBN: 978-0-470-69951-5.
- Aadahl M, Linneberg A, Moller TC, et al. Motivational counseling to reduce sitting time: a community-based randomized controlled trial in adults. Am J Prev Med. 2014; 47(5):576-586.
- Alkhajah TA, Reeves MM, Eakin EG, Winkler EA, Owen N, Healy GN. Sit-stand workstations: a pilot intervention to reduce office sitting time. Am J Prev Med. 2012;43(3):298-303.
- Butler KM, Ramos JS, Buchanan CA, Dalleck LC. Can reducing sitting time in the university setting improve the cardiometabolic health of college students? *Diabetes Metab Syndr Obes*. 2018;11:603-610.
- Danquah IH, Kloster S, Holtermann A, et al. Take a Stand!—a multi-component intervention aimed at reducing sitting time among office workers—a cluster randomized trial. Int J Epidemiol. 2017;46(1):128-140.
- Healy GN, Eakin EG, LaMontagne AD, et al. Reducing sitting time in office workers: short-term efficacy of a multicomponent intervention. *Prev Med.* 2013;57(1):43-48.
- Healy GN, Winkler E, Eakin EG, et al. A cluster RCT to reduce workers' sitting time: impact on cardiometabolic biomarkers. Med Sci Sports Exerc. 2017;49(10):2032-2039.
- MacEwen BT, Saunders TJ, MacDonald DJ, Burr JF. Sit-stand desks to reduce workplace sitting time in office workers with abdominal obesity: a randomized controlled trial. J Phys Act Health. 2017;14(9):710-715.
- Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64(4):401-406.
- Murad MH. Clinical practice guidelines: a primer on development and dissemination. *Mayo Clinic Proc.* 2017;92(3):423-433.
- Wood PD. Impact of experimental manipulation of energy intake and expenditure on body composition. *Crit Rev Food Sci Nutr.* 1993;33(4-5):369-373.
- Hanson S, Jones A. Is there evidence that walking groups have health benefits? A systematic review and meta-analysis. Br J Sports Med. 2015;49(11):710-715.
- Batsis JA, Mackenzie TA, Bartels SJ, Sahakyan KR, Somers VK, Lopez-Jimenez F. Diagnostic accuracy of body mass index to identify obesity in older adults: NHANES 1999–2004. Int J Obes (Lond). 2016;40(5):761-767.
- 43. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, et al. Normal-weight central obesity: implications for total and cardiovascular mortalitymortality risk in persons with normalweight central obesity. Ann Intern Med. 2015;163(11):827-835.

- Medina-Inojosa J, Somers V, Jenkins S, et al. Validation of a white-light 3D body volume scanner to assess body composition. Obes Open Access. 2017;3(1).
- Medina-Inojosa J, Somers VK, Ngwa T, Hinshaw L, Lopez-Jimenez F. Reliability of a 3D body scanner for anthropometric measurements of central obesity. Obes Open Access. 2016;2(3).
- Carr LJ, Swift M, Ferrer A, Benzo R. Cross-sectional examination of long-term access to sit-stand desks in a professional office setting. Am J Prev Med. 2016;50(1):96-100.
- 47. Chaput JP, Saunders TJ, Tremblay MS, Katzmarzyk PT, Tremblay A, Bouchard C. Workplace standing time and the incidence of obesity and type 2 diabetes: a longitudinal study in adults. BMC Public Health. 2015;15:111.
- **48.** Santos J, Benite-Ribeiro S, Queiroz G, Duarte JA. The interrelation between aPKC and glucose uptake in the skeletal muscle

during contraction and insulin stimulation. *Cell Biochem Funct.* 2014;32(3):621-624.

- **49.** Tikkanen O, Haakana P, Pesola AJ, et al. Muscle activity and inactivity periods during normal daily life. *PloS One*. 2013; 8(1):e52228.
- Cai M, Zou Z. Effect of aerobic exercise on blood lipid and glucose in obese or overweight adults: a meta-analysis of randomised controlled trials. Obes Res Clin Pract. 2016;10(5):589-602.
- Kelley GA, Kelley KS, Tran ZV. Aerobic exercise, lipids and lipoproteins in overweight and obese adults: a meta-analysis of randomized controlled trials. *Int J Obes (Lond)*. 2005;29(8):881-893.
- Batacan RB, Duncan MJ, Dalbo VJ, Tucker PS, Fenning AS. Effects of light intensity activity on CVD risk factors: a systematic review of intervention studies. *BioMed Res Int.* 2015;2015: 596367.